亚砷酸(Arsenious Acid) - 在研适应症：急性早幼粒细胞白血病，乳腺癌，结肠癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Arsenious Acid and Sodium Chloride、arsenic trihydroxide、arsenous acid

+ [3]

靶点-

作用机制-

治疗领域

肿瘤免疫系统疾病心血管疾病+ [7]

在研适应症

急性早幼粒细胞白血病乳腺癌结肠癌+ [5]

非在研适应症-

原研机构

哈尔滨医科大学

在研机构

哈尔滨医大药业股份有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式AsH3O3

InChIKeyGCPXMJHSNVMWNM-UHFFFAOYSA-N

CAS号13464-58-9

关联

3

项与亚砷酸相关的临床试验

NCT06678048 / Recruiting临床2期IIT

A Single-Arm, Two Stage, Phase II Study of Arsenous Acid Combined With Palliative Chemotherapy for Refractory Triple-Negative Breast Cancer

The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of treatment.

开始日期2024-11-06

申办/合作机构

中山大学

CTRI/2024/06/069509 / Not yet recruiting临床3期IIT

Comparison Of Gingival Trauma Induced by Aluminium Trihydroxide Air Polishing Powder With Sodium Bicarbonate Air Polishing Powder In Subjects With Plaque Induced Gingivitis: A Randomized Controlled Clinical Trial. - nil

开始日期2024-07-05

申办/合作机构-

NCT01573312 / Completed临床1期IIT

A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered With and Without AS03 Adjuvant: Standard & Systems Biology Analyses

This is a single center, randomized, double-blinded, controlled, Phase I, small targeted prospective study in healthy male and non-pregnant female subjects, 18 to 49 years old, inclusive, designed to determine the safety, reactogenicity, and immunogenicity of an intramuscular subvirion inactivated monovalent influenza A/H5N1 (HA of A/Indonesia/05/2005) virus vaccine manufactured by Sanofi Pasteur administered at 3.75 mcg per dose given with or without AS03 adjuvant manufactured by GSK. In the study, each subject will receive two doses administered 28 days apart. This study will use a systems biology approach to assess the human early gene and protein signatures expressed at Days 1, 3, 7, and 28 after the first vaccination. The systems data will be integrated with immunogenicity and reactogenicity data to develop a systems model of the human immune response to A/H5N1 vaccine with or without AS03 adjuvant.

开始日期2012-05-24

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与亚砷酸相关的临床结果

登录后查看更多信息

100 项与亚砷酸相关的转化医学

登录后查看更多信息

100 项与亚砷酸相关的专利（医药）

登录后查看更多信息

19

项与亚砷酸相关的文献（医药）

2024-01-05·Medicine

A case report of acute promyelocytic leukemia with mycosis fungoides

Article

作者: Zhao, Yongqin ; Zhu, Yejing ; Zhang, Fang ; Zhou, Hongjing ; Dong, Shasha

Rationale:Acute promyelocytic leukaemia (APL) is a rare subtype of acute myelogenous leukaemia. With advances in treatment regimens, namely, introduction of all-trans-retinoicacid, outcomes have drastically improved, its side effects should not be ignored. Mycosis fungoides is one of the side effects of all-trans-retinoicacid treatment, but it may also be a clinical manifestation before disease progression. However, it rarely appears and is easily overlooked. This leads to being easily misled during the treatment process, affecting the treatment plan, and resulting in adverse consequences. Therefore, early identification and judgment can not only provide appropriate treatment options, but also prevent and treat further disease progression.Patient concerns:The patient was hospitalized for pancytopaenia. After completing the examination, the patient was finally diagnosed with acute promyelocytic leukaemia (acute myelogenous leukaemia-M3). We administered tretinoin and arsenous acid. Evaluation of the treatment effect on the 7th day after chemotherapy showed that the bone marrow morphology showed complete remission. After the second course of chemotherapy, the patient developed red miliary macular papules, which gradually worsened. After completing relevant inspections, Considering that the cases was complicated with skin mycosis fungoides, the patient was treated with budesonide ointment and methylprednisolone as chemotherapy.Diagnoses:Upon examination, the patient was initially diagnosed with acute promyelocytic leukaemia. Evaluation of the treatment effect on the 7th day after chemotherapy showed that the bone marrow morphology showed complete remission. After the second course of chemotherapy, we discovered the patient was diagnosed with skin mycosis fungoides.Interventions:Systemic chemotherapy is first given when a patient was diagnosed with acute promyelocytic leukaemia. After the patient happened skin mycosis fungoides, We have adjusted the treatment plan and supplemented it with other treatment plans based on the original chemotherapy, After 2 months of treatment, his condition gradually improved.Outcomes:All-trans-retinoicacid in the treatment of APL must be given attention because mycosis fungoides should not only be distinguished from infectious diseases but also be further assessed with regard to disease progression and metastasis.Lessons:Acute promyelocytic leukemia needs to be treated with arsenic trioxide. All-trans-retinoicacid in the treatment of APL must be given attention mycosis fungoides. Early diagnosis can guide accurate treatment, which is of great help in alleviating the pain of patients and improving the cure rate.

2023-06-14·bioRxiv : the preprint server for biology

Evidence of Disrupted-in Schizophrenia 1 (DISC1) as an arsenic binding protein and implications regarding its role as a translational activator.

作者: Stewart, Charles E ; Warren, Grant ; Roche, Julien ; Watanabe, Muneaki ; Shin, Juyoung ; Khu, Tung Mei

Disrupted-in-schizophrenia-1 (DISC1) is a scaffold protein that plays a pivotal role in orchestrating signaling pathways involved in neurodevelopment, neural migration, and synaptogenesis. Among those, it has recently been reported that the role DISC1 in the Akt/mTOR pathway can shift from a global translational repressor to a translational activator in response to oxidative stress induced by arsenic. In this study we are providing evidence that DISC1 can directly bind arsenic via a C-terminal cysteine motif (C-X-C-X-C). A series of fluorescence-based binding assays were conducted with a truncated C-terminal domain construct of DISC1 and a of series of single, double, and triple cysteine mutants. We found that arsenous acid, a trivalent arsenic derivative, specifically binds to the C-terminal cysteine motif of DISC1 with low micromolar affinity. All three cysteines of the motif are required for high-affinity binding. Electron microscopy experiments combined with in silico structural predictions revealed that that the C-terminal of DISC1 forms an elongated tetrameric complex. The cysteine motif is consistently predicted to be located within a loop, fully exposed to solvent, providing a simple molecular framework to explain the high-affinity of DISC1 toward arsenous acid. This study sheds light on a novel functional facet of DISC1 as an arsenic binding protein and highlights its potential role as both a sensor and translational modulator within the Akt/mTOR pathway.

2021-12-01·Nature Nanotechnology1区 · 材料科学

Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects

1区 · 材料科学

Article

作者: Shi, Jinan ; Wei, Wei ; Liu, Liyuan ; Ma, Guanghui ; Yue, Hua ; Yu, Siyao ; Wang, Shuang ; Gao, Zirui ; Hu, Yuxing ; Ma, Ding ; Zhou, Wu ; Li, Yuhua ; Wang, Changlong ; Li, Feng ; Zhao, Chaochao ; Zhang, Wei ; He, Yanjie ; Li, Hui

Trivalent arsenic (As^III) is an effective agent for treating patients with acute promyelocytic leukaemia, but its ionic nature leads to several major limitations like low effective concentrations in leukaemia cells and substantial off-target cytotoxicity, which limits its general application to other types of leukaemia. Here, building from our clinical discovery that cancerous cells from patients with different leukaemia forms featured stable and strong expression of CD71, we designed a ferritin-based As nanomedicine, As@Fn, that bound to leukaemia cells with very high affinity, and efficiently delivered cytotoxic As^III into a large diversity of leukaemia cell lines and patient cells. Moreover, As@Fn exerted strong anti-leukaemia effects in diverse cell-line-derived xenograft models, as well as in a patient-derived xenograft model, in which it consistently outperformed the gold standard, showing its potential as a precision treatment for a variety of leukaemias.

100 项与亚砷酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	亚砷酸	L01	DB04456

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性早幼粒细胞白血病	中国	哈尔滨医大药业股份有限公司	-
乳腺癌	中国	哈尔滨医大药业股份有限公司	-
结肠癌	中国	哈尔滨医大药业股份有限公司	-
肝癌	中国	哈尔滨医大药业股份有限公司	-
肺癌	中国	哈尔滨医大药业股份有限公司	-
多发性骨髓瘤	中国	哈尔滨医大药业股份有限公司	-
胰腺癌	中国	哈尔滨医大药业股份有限公司	-
宫颈癌	中国	哈尔滨医大药业股份有限公司	-